EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN (IPTA) MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH THE ANTI-C5 MONOCLONAL ANTIBODY (MAB) TESIDOLUMAB (TESI)

Authors
Category Primary study
ConferenceEHA2023 Hybrid Congress
Year 2023
This article has no abstract
Epistemonikos ID: b2e877107860c32b324c2c626658ab354dcde7c1
First added on: Apr 25, 2026